Key facts
| Price (PPV) | 205 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | losartanhydrochlortiazide |
| Class | Agents acting on the renin-angiotensin system |
| ATC code | C09DA01 |
| Manufacturer | PHI |
| Presentation | Boite de 60 |
| Nature | Médicament |
| Hospital price | 128.60 MAD |
| Data collected on | 9/8/2026 |
Indications
Traitement de l’hypertension artérielle essentielle chez les patients dont la pression artérielle n’est pas suffisamment contrôlée par le losartan ou l’hydrochlorothiazide en monothérapie.
Find an open pharmacy
On-call pharmacies near you
Same-strength alternatives — cheapest first
Bi-Hyplos 50 mg / 12.5 mg (SPIMACO) contains the same active substance as Co-Anginib 50 mg / 12.5 mg (Losartan | Hydrochlortiazide) at the same strength, but in a different pack: Boite de 14 at 60.60 MAD, i.e. 4.33 MAD per unit against 3.42 MAD for Co-Anginib 50 mg / 12.5 mg. The public sale price is set by the Ministry of Health: it is identical in every pharmacy.
| Product | Manufacturer | Pack | PPV | Unit price |
|---|---|---|---|---|
| Bi-Hyplos 50 mg / 12.5 mg | SPIMACO | Boite de 14 | 60.60 MAD | 4.33 / unit |
| Co-Tanzaar 50 mg / 12.5 mg | AFRIC-PHAR | Boite de 14 | 60.60 MAD | 4.33 / unit |
| Ancine Plus 50 mg / 12.5 mg | NOVOPHARMA | Boite de 30 | 64.20 MAD | 2.14 / unit |
| Bi-Hyplos 50 mg / 12.5 mg | SPIMACO | Boite de 28 | 90 MAD | 3.21 / unit |
| Co-Rosar 50 mg / 12.5 mg | PHARMIS | Boite de 28 | 101 MAD | 3.61 / unit |
| Co Medzar 50 mg / 12.5 mg | POLYMEDIC | Boite de 30 | 106.70 MAD | 3.56 / unit |
| Co-Anginib 50 mg / 12.5 mg | PHI | Boite de 30 | 114.30 MAD | 3.81 / unit |
| Diprezar 50 mg / 12.5 mg | BOTTU S.A. | Boîte de 30 | 114.30 MAD | 3.81 / unit |
Substituting a generic is the pharmacist's decision; for medicines listed in schedules A, B and C it still requires a prescription. Public sale prices published by the Directorate of Medicines and Pharmacy, recorded on 9/8/2026.
About Co-Anginib 50 mg / 12.5 mg
Co-Anginib 50 mg / 12.5 mg belongs to the agents acting on the renin-angiotensin system therapeutic class. In Morocco, this drug is marketed by PHI and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Co-Anginib 50 mg / 12.5 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Co-Anginib 50 mg / 12.5 mg
Answers to common questions from Moroccan patients about this drug.